Literature DB >> 18280058

Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery.

Todd W Flannery1, Mohan Suntharalingam, William F Regine, Lawrence S Chin, Mark J Krasna, Michael K Shehata, Martin J Edelman, Marnie Kremer, Roy A Patchell, Young Kwok.   

Abstract

PURPOSE: To report the outcome of patients with synchronous, solitary brain metastasis from non-small-cell lung cancer (NSCLC) treated with gamma knife stereotactic radiosurgery (GKSRS). PATIENTS AND METHODS: Forty-two patients diagnosed with synchronous, solitary brain metastasis from NSCLC were treated with GKSRS between 1993 and 2006. The median Karnofsky performance status (KPS) was 90. Patients had thoracic Stage I-III disease (American Joint Committee on Cancer 2002 guidelines). Definitive thoracic therapy was delivered to 26/42 (62%) patients; 9 patients underwent chemotherapy and radiation, 12 patients had surgical resection, and 5 patients underwent preoperative chemoradiation and surgical resection.
RESULTS: The median overall survival (OS) was 18 months. The 1-, 2-, and 5-year actuarial OS rates were 71.3%, 34.1%, and 21%, respectively. For patients who underwent definitive thoracic therapy, the median OS was 26.4 months compared with 13.1 months for those who had nondefinitive therapy, and the 5-year actuarial OS was 34.6% vs. 0% (p < 0.0001). Median OS was significantly longer for patients with a KPS >or=90 vs. KPS < 90 (27.8 months vs. 13.1 months, p < 0.0001). The prognostic factors significant on multivariate analysis were definitive thoracic therapy (p = 0.020) and KPS (p = 0.001).
CONCLUSIONS: This is one of the largest series of patients diagnosed with synchronous, solitary brain metastasis from NSCLC treated with GKSRS. Definitive thoracic therapy and KPS significantly impacted OS. The 5-year OS of 21% demonstrates the potential for long-term survival in patients treated with GKSRS; therefore, patients with good KPS should be considered for definitive thoracic therapy.

Entities:  

Mesh:

Year:  2008        PMID: 18280058     DOI: 10.1016/j.ijrobp.2007.12.031

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  39 in total

1.  Correspondence (letter to the editor): Treatment option should not be withheld.

Authors:  Simon Futterer
Journal:  Dtsch Arztebl Int       Date:  2010-10-15       Impact factor: 5.594

2.  Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients.

Authors:  Taher Abu Hejleh; Barry R Deyoung; Eric Engelman; Jeremy M Deutsch; Bridget Zimmerman; Thorvardur R Halfdanarson; Daniel J Berg; Kalpaj R Parekh; William R Lynch; Mark D Iannettoni; Sudershan Bhatia; Gerald Clamon
Journal:  World J Gastrointest Oncol       Date:  2012-05-15

Review 3.  Surgery versus radiosurgery for patients with a solitary brain metastasis from non-small cell lung cancer.

Authors:  R Fuentes; X Bonfill; J Exposito
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

4.  Outcome and prognostic factors in single brain metastases from small-cell lung cancer.

Authors:  Denise Bernhardt; Sebastian Adeberg; Farastuk Bozorgmehr; Nils Opfermann; Juliane Hörner-Rieber; Laila König; Jutta Kappes; Michael Thomas; Andreas Unterberg; Felix Herth; Claus Peter Heußel; Arne Warth; Jürgen Debus; Martin Steins; Stefan Rieken
Journal:  Strahlenther Onkol       Date:  2017-10-30       Impact factor: 3.621

5.  Effect of chemotherapy on survival after whole brain radiation therapy for brain metastases: a single-center retrospective analysis.

Authors:  Hiroshi Mayahara; Minako Sumi; Yoshinori Ito; Syuhei Sekii; Kana Takahashi; Kouji Inaba; Yuuki Kuroda; Naoya Murakami; Madoka Morota; Jun Itami
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-23       Impact factor: 4.553

6.  A novel paradigm in the treatment of oligometastatic non-small cell lung cancer.

Authors:  Salma K Jabbour; Parima Daroui; Dirk Moore; Edward Licitra; Molly Gabel; Joseph Aisner
Journal:  J Thorac Dis       Date:  2011-03       Impact factor: 2.895

7.  Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis.

Authors:  Dianhe Li; Xiaoxia Zhu; Haofei Wang; Min Qiu; Na Li
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

8.  Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC).

Authors:  Paul Martin Putora; Silvia Ess; Cedric Panje; Thomas Hundsberger; Karin van Leyen; Ludwig Plasswilm; Martin Früh
Journal:  Clin Exp Metastasis       Date:  2015-01-28       Impact factor: 5.150

9.  Clinical Impact of Frequent Surveillance Imaging in the First Year Following Chemoradiation for Locally Advanced Non-small-cell Lung Cancer.

Authors:  Quoc-Anh Ho; Nima K Harandi; Megan E Daly
Journal:  Clin Lung Cancer       Date:  2016-11-21       Impact factor: 4.785

10.  Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis.

Authors:  Jose Luis Lopez Guerra; Daniel Gomez; Yan Zhuang; David S Hong; John V Heymach; Stephen G Swisher; Steven H Lin; Ritsuko Komaki; James D Cox; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-13       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.